Understanding the logistics of oncolytic virotherapy

  • Thread starter chops369
  • Start date
In summary, the authors of the paper, "Oncolytic Poxvirus Armed with Fas Ligand Leads to Induction of Cellular Fas Receptor and Selective Viral Replication in FasR Negative Cancer," propose using an oncolytic virus to deliver Fas ligand to cells in hopes of inducing apoptosis in normal cells and allowing for full replication in cancer cells. However, the effectiveness of this method is questionable as it may also induce apoptosis in adjacent normal cells. Additionally, there is always a risk that the virus may spread to other areas of the body.
  • #1
chops369
56
0
I have questions about a particular paper: Oncolytic Poxvirus Armed with Fas Ligand Leads to Induction of Cellular Fas Receptor and Selective Viral Replication in FasR Negative Cancer

The authors explain that they're using an oncolytic virus to deliver membrane-bound Fas ligand to cells in a non-specific manner. Their hypothesis is that apoptosis will be induced in normal cells which are FasR+, thereby aborting viral replication, whereas in cancer cells that have knocked out FasR, the virus will replicate fully and lyse the cell.

I'm confused as to how inducing apoptosis in this way will lead to abortive replication in normal cells. If FasL is membrane-bound, won't the virus-infected cell expressing it induce apoptosis in an adjacent, normal cell? That doesn't really seem efficacious.

Am I incorrect in assuming that somewhere along the line, there will be a normal cell that allows for productive replication of the virus?
 
Biology news on Phys.org
  • #2
yeah that's the problem if you inject a vial of fluid of virus that might enter the blood stream and go to other places. The idea that favors anti cancer is that cancer cells usually have a higher metabolic requirement which will become the target of most of the virus. You can always modify the virus to bind with unique cancer receptors, but who knows how well that will go on a live person.
 

1. What is oncolytic virotherapy?

Oncolytic virotherapy is a type of cancer treatment that uses viruses to specifically target and destroy cancer cells in the body. These viruses are genetically modified to selectively infect and replicate in cancer cells, ultimately leading to their death.

2. How does oncolytic virotherapy work?

Oncolytic viruses are designed to infect and replicate within cancer cells, causing them to burst and release more viruses. This process can also trigger an immune response, leading to further destruction of cancer cells. Additionally, some oncolytic viruses can be engineered to carry genes that enhance their therapeutic effects.

3. What types of cancer can be treated with oncolytic virotherapy?

Oncolytic virotherapy has shown promise in treating a variety of cancers, including melanoma, lung cancer, breast cancer, and many others. However, research is ongoing and the effectiveness of this treatment may vary depending on the type and stage of cancer.

4. What are the potential benefits of oncolytic virotherapy?

Oncolytic virotherapy has several potential benefits compared to traditional cancer treatments. These include fewer side effects, targeted and specific cancer cell destruction, potential for combination therapy with other treatments, and the ability to potentially overcome drug resistance.

5. What are the challenges and limitations of oncolytic virotherapy?

While oncolytic virotherapy shows promise, there are still many challenges and limitations that need to be addressed. These include the potential for the virus to cause harm to healthy cells, difficulty in delivering the virus to the tumor site, and the potential for the virus to become less effective over time due to the body's immune response.

Similar threads

  • Biology and Medical
Replies
14
Views
2K
  • Biology and Medical
Replies
31
Views
5K
Replies
1
Views
1K
  • Biology and Medical
Replies
5
Views
5K
  • Biology and Medical
3
Replies
100
Views
6K
Back
Top